Recent Updates
Recently added Catalysts
FHTX Positive Sentiment

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Tuesday, October 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Foghorn Therapeutics Inc. will participate in the BMO Oncology Summit on October 8, 2024, in New York, NY. The company focuses on developing innovative medicines aimed at correcting abnormal gene expression to treat serious diseases. Their Gene Traffic Control platform promises to advance treatment options, particularly in oncology, and has a broad pipeline that may impact a wide array of diseases.
Price reaction · baseline $9.31 (2024-09-30 close) · hit after-hours · clean, no other FHTX news in the window
day 0 close
-6.9%
day 1
-10.5%
day 3 · peak
-15.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a reputable oncology summit highlights industry recognition.
  • Potential for transformative medicines targeting serious diseases.
  • Strong focus on oncology with a broad pipeline of treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
5.9%
average across 4 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
FHD-286
Phase 2 · Small Cell Lung Cancer

Full Press Release Details

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
About Foghorn Therapeutics
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)

Frequently Asked Questions

What is Foghorn Therapeutics known for?

Foghorn Therapeutics develops medicines that correct abnormal gene expression.

When is Foghorn participating in investor meetings?

Foghorn will attend the BMO Oncology Summit on October 8, 2024.

What is the focus of Foghorn’s research?

Foghorn initially focuses on oncology treatments for various diseases.

What platform does Foghorn use for its therapies?

Foghorn uses the Gene Traffic Control® platform for its pipeline.

Where is Foghorn Therapeutics located?

Foghorn Therapeutics is based in Cambridge, Massachusetts.

ShareAdd on Google
Tags: FHTX Viatris Investor Conferences Healthcare Foghorn Therapeutics oncology summit gene expression New York
Last updated: Oct 1, 2024

Biotech snapshot

Cash runway
$168M liquidity · $6M/mo burn
~28 mo
Minimal dilution risk
Lead asset
FHD-286Phase 2
Small Cell Lung Cancer →

Catalyst track record

+56%
best trade around FHTX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for FHTX.

See every catalyst's timing & PoA →